SPY304.32+1.35 0.45%
DIA254.29-0.06 -0.02%
IXIC9,489.87+120.88 1.29%

Roth Capital Upgrades Allogene Therapeutics to Buy, Announces $60 Price Target

Roth Capital analyst Tony Butler upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and announces $60 price target.

Benzinga · 05/19/2020 10:34

Roth Capital analyst Tony Butler upgrades Allogene Therapeutics (NASDAQ:ALLO) from Neutral to Buy and announces $60 price target.